Catalyst Pharmaceuticals, Inc. (CPRX)

Jul 15, 2026 - CPRX was delisted (reason: acquired by Angelini Pharma)

31.49

0.00 (0.00%)

Inactive · Last trade price on Jul 15, 2026

Catalyst Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	755.86	709.17	517.55	137.64	298.4	171.45
Short-Term Investments	-	-	-	-	-	19.82
Cash & Short-Term Investments	755.86	709.17	517.55	137.64	298.4	191.27
Cash Growth	30.17%	37.02%	276.03%	-53.87%	56.01%	36.35%
Accounts Receivable	130.83	126.48	65.48	53.51	10.44	6.62
Inventory	34.93	37.17	19.54	15.64	6.81	7.87
Other Current Assets	18.77	21.22	21.04	12.54	5.17	4.35
Total Current Assets	940.39	894.03	623.61	219.33	320.81	210.11
Net Property, Plant & Equipment	2.85	2.97	3.58	3.7	3.62	3.98
Other Intangible Assets	121.97	131.67	156.67	194.05	32.47	-
Long-Term Investments	27.29	22.54	21.56	16.49	-	-
Other Long-Term Assets	55.11	52.77	45.98	36.54	18.74	23.71
Total Assets	1,148	1,104	851.41	470.11	375.63	237.79

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	7.15	11.2	16.59	14.8	3.98	2.77
Accrued Expenses	125.25	135.95	104.09	61.27	53.61	24.3
Total Current Liabilities	132.4	147.15	120.68	76.06	57.59	27.06
Long-Term Leases	2.24	2.35	2.79	3.19	3.56	3.89
Other Long-Term Liabilities	0.28	0.21	0.32	2.98	14.06	-
Total Long-Term Liabilities	2.52	2.56	3.1	6.17	17.62	3.89
Total Liabilities	134.91	149.71	123.78	82.23	75.21	30.96

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.12	0.12	0.12	0.11	0.11	0.1
Additional Paid-in Capital	489.22	479.96	442.29	266.49	250.43	233.19
Accumulated Other Comprehensive Income	0.01	-	0.06	0.01	0.02	-0.15
Retained Earnings	523.35	474.19	285.16	121.27	49.86	-26.31
Shareholders' Equity	1,013	954.27	727.63	387.88	300.42	206.83
Total Liabilities & Equity	1,148	1,104	851.41	470.11	375.63	237.79

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	2.24	2.35	2.79	3.19	3.56	3.89
Net Cash (Debt)	753.62	706.82	514.77	134.45	294.84	187.37
Net Cash Growth	30.39%	37.31%	282.87%	-54.40%	57.35%	33.57%
Net Cash Per Share	5.92	5.55	4.12	1.18	2.65	1.74
Book Value	1,013	954.27	727.63	387.88	300.42	206.83
Book Value Per Share	7.96	7.50	5.82	3.41	2.70	1.92
Tangible Book Value	890.73	822.59	570.96	193.83	267.95	206.83
Tangible Book Value Per Share	7.00	6.46	4.57	1.70	2.41	1.92

SEC Filings: 10-K · 10-Q